Evidence map›Paper›PMID 35598202›Full record

ArticleThe oncologist2022

Association of CD274 (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer.

Karthikeyan Murugesan, Dexter X Jin, Leah A Comment, David Fabrizio, Priti S Hegde, Julia A Elvin, Brian Alexander, Mia A Levy, Garrett M Frampton, Meagan Montesion and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025
    Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Karthikeyan MurugesanFoundation Medicine, Inc., Cambridge, MA, USA.ORCID 0000-0002-2275-1126
Dexter X JinFoundation Medicine, Inc., Cambridge, MA, USA.
Leah A CommentFoundation Medicine, Inc., Cambridge, MA, USA.
David FabrizioFoundation Medicine, Inc., Cambridge, MA, USA.
Priti S HegdeFoundation Medicine, Inc., Cambridge, MA, USA.
Julia A ElvinFoundation Medicine, Inc., Cambridge, MA, USA.
Brian AlexanderFoundation Medicine, Inc., Cambridge, MA, USA.
Mia A LevyFoundation Medicine, Inc., Cambridge, MA, USA.
Garrett M FramptonFoundation Medicine, Inc., Cambridge, MA, USA.
Meagan MontesionFoundation Medicine, Inc., Cambridge, MA, USA.
Sameek RoychowdhuryJames Cancer Hospital, Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Razelle KurzrockDivision of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Jeffrey S RossFoundation Medicine, Inc., Cambridge, MA, USA.
Lee A AlbackerFoundation Medicine, Inc., Cambridge, MA, USA.ORCID 0000-0002-5070-1783
Richard S P HuangFoundation Medicine, Inc., Cambridge, MA, USA.ORCID 0000-0001-8395-5168
Foundation Medicine (United States)Medical College of Wisconsin · USSUNY Upstate Medical University · USThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe sought to characterize response to immune checkpoint inhibitor (ICI) in non-squamous non-small cell lung cancer (NSCLC) across various CD274 copy number gain and loss thresholds and identify an optimal cutoff. MATERIALS AND

methodsA de-identified nationwide (US) real-world clinico-genomic database was leveraged to study 621 non-squamous NSCLC patients treated with ICI. All patients received second-line ICI monotherapy and underwent comprehensive genomic profiling as part of routine clinical care. Overall survival (OS) from start of ICI, for CD274 copy number gain and loss cohorts across varying copy number thresholds, were assessed.

resultsAmong the 621 patients, patients with a CD274 CN greater than or equal to specimen ploidy +2 (N = 29) had a significantly higher median (m) OS when compared with the rest of the cohort (N = 592; 16.1 [8.9-37.3] vs 8.6 [7.1-10.9] months, hazard ratio (HR) = 0.6 [0.4-1.0], P-value = .05). Patients with a CD274 copy number less than specimen ploidy (N = 299) trended toward a lower mOS when compared to the rest of the cohort (N = 322; 7.5 [5.9-11.3] vs 9.6 [7.9-12.8] months, HR = 0.9 [0.7-1.1], P-value = .3).

conclusionThis work shows that CD274 copy number gains at varying thresholds predict different response to ICI blockade in non-squamous NSCLC. Considering these data, prospective clinical trials should further validate these findings, specifically in the context of PD-L1 IHC test results.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsB7-H1 AntigenDNA Copy Number VariationsHumansImmune Checkpoint InhibitorsProspective StudiesB7-H1 AntigenCD274 protein, humanImmune Checkpoint InhibitorsCD274comprehensive genomic profilingimmunotherapynon-small cell lung cancerreal world evidence

Identifiers

PMID35598202
PMCPMC9438920
OpenAlexW4226316837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.